Browse studies

Find your next paid study

1,241 recruiting studies matching your filters

THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins

Background: Allergic and inflammatory conditions have been increasing over the years. Many factors may play a role in this. Every day, people are exposed to p…

AllergicInflammatory

Estimated

~$10 – $5,625

National Institute of Allergy and Infectious Diseases (NIAID)NCT07271381

Phase 3

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epider…

Advanced Non-small Cell Lung Cancer, HER2 Mutation

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lym…

Small Cell Lung Cancer

Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer re…

Lung Non-Small Cell Carcinoma

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07388524

Phase 1

A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 …

Ovarian CancerNon-small Cell Lung Cancer

Estimated

~$10 – $8,750

Tubulis GmbHNCT06303505

Phase 3

A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy and Safety of Remibrutinib (LOU064) in Adult and Adolescent Participants With IgE-mediated Food Allergy

The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked …

IgE-Mediated Food AllergyPeanut AllergyCow Milk Allergy+1 more

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07768371

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and mo…

B-cell MalignancyMarginal Zone LymphomaFollicular Lymphoma+6 more

Estimated

~$10 – $7,500

BeOne MedicinesNCT05006716

Observational

Upper Extremity Vascularized Composite Allotransplantation: A Prospective Interventional Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

The primary objective of this study is to evaluate the 5-year (60-month) allograft survival rate of upper extremity vascularized composite allotransplantation …

Functional RecoveryUpper Extremity Vascularized Composite Allotransplantation

Estimated

~$10 – $6,250

Yale UniversityNCT07810790

Phase 3

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet che…

Non-Small Cell Lung Cancer (NSCLC)

A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction

The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval …

Brain Metastases, AdultBrain Tumor - MetastaticBrain Metastases From Non-small Cell Lung Cancer (NSCLC)+1 more

Estimated

~$10 – $7,500

Ayal A. Aizer, MDNCT07132190

Phase 3

A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)

The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients w…

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

Estimated

~$10 – $7,500

AstraZenecaNCT07509151

Phase 1

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-labe…

Locally Advanced Solid Tumor

Estimated

~$10 – $8,750

Tango Therapeutics, Inc.NCT05732831